樂華娛樂集團(02306.HK)公開發售獲超購27.68倍 定價4.08港元/股
格隆匯1月18日丨樂華娛樂集團(02306.HK)公佈招股結果,發售價定為4.08港元/股,為招股價範圍(3.91港元-5.06港元)的偏下限;香港公開發售部分錄得超額認購約27.68倍;每手3000股計,一手中籤率50%;預計將於1月19日掛牌;聯席保薦人為中信建投國際及招商證券國際。
公司上市引入4名基石投資者,包括Sun Mass Energy、貓眼香港、丁世家及好贊資產,合共認購3794.4萬股,佔緊隨全球發售完成後公司總股本的約4.37%及全球發售項下股份總數的約31.61%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.